Skip to Content

Oritavancin use while Breastfeeding

Drugs containing Oritavancin: Orbactiv, Kimyrsa

Medically reviewed by Drugs.com. Last updated on Feb 1, 2021.

Oritavancin Levels and Effects while Breastfeeding

Summary of Use during Lactation

Because oritavancin is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Monitor the infant for possible effects on the gastrointestinal tract, such as diarrhea, vomiting, and candidiasis (e.g., thrush, diaper rash). However, because there is no published experience with oritavancin during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Oritavancin

CAS Registry Number

171099-57-3

Drug Class

  • Breast Feeding
  • Lactation
  • Anti-Infective Agents
  • Anti-Bacterial Agents
  • Glycopeptides
  • Lipoglycopeptides

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.